FUSTER
ET AL., ACC/AHA/ESC GUIDELINES FOR THE MANAGEMENT OF
PATIENTS WITH ATRIAL FIBRILLATION
JACC Vol.38, August 2001:1231-65
ACC/AHA/ESC
Guidelines for the Management of Patients with Atrial
Fibrillation - Executive Summary
Figures
& Tables
Figure
1. Patterns of atrial fibrillation.
Figure
2. Prevalence of AF in 2 American epidemiological
studies.
Figure
3. Relative risk of stroke and mortality in patients
with AF compared with patients without AF.
Figure 4. Arrhythmia-free
survival after electrical cardioversion in patients
with persistent atrial fibrillation.
Figure
5. Hypothetical illustration of cardioversion failure.
Figure
6. Antithrombotic therapy for prevention of stroke
(ischemic and hemorrhagic) in patients with nonvalvular
AF: adjusted-dose warfarin compared with placebo.
Figure
7. Adjusted
odds ratios for ischemic stroke and intracranial bleeding
in relation to intensity of anticoagulation in randomized
trials of antithrombotic therapy for patients with atrial
fibrillation.
Figure
8. Antithrombotic therapy for prevention of stroke
(ischemic and hemorrhagic) in patients with nonvalvular
AF: warfarin compared with aspirin and aspirin compared
with placebo.
Figure
9. Pharmacological management of patients with newly
discovered atrial fibrillation.
Figure
10. Pharmacological management of patients with
recurrent paroxysmal atrial fibrillation.
Figure
11. Antiarrhythmic drug therapy to maintain sinus
rhythm in patients with recurrent paroxysmal or persistent
atrial fibrillation.
Figure
12. Pharmacological management of patients with
recurrent persistent or permanent atrial fibrillation.
Table
1. Minimum and Additional Clinical Evaluation in
Patients With Atrial Fibrillation.
Table
2. Vaughan Williams Classification of Antiarrhythmic
Drug Actions.
Table
3. Typical Doses of Drugs Used to Maintain Sinus
Rhythm in Patients With Atrial Fibrillation.
Table
4. Types of Proarrhythmia During Treatment With
Various Antiarrhythmic Drugs for Atrial Fibrillation
or Atrial Flutter According to the Vaughan Williams
Classification.
Table
5. Pharmacological Treatment Before Cardioversion
in Patients With Persistent Atrial Fibrillation: Effects
of Various Antiarrhythmic Drugs on Acute and Subacute
Outcome of Transthoracic Direct Current Shock.
Table
6. Intravenous Pharmacological Agents for Heart
Rate Control in Patients With Atrial Fibrillation.
Table
7. Recommendations for Use of Orally Administered
Pharmacological Agents for Heart Rate Control in Patients
With Atrial Fibrillation.
Table
8. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation.
Table
9. Published Risk-Stratification Schemes for Primary
Prevention of Thromboembolism in Patients With Nonvalvular
Atrial Fibrillation.
Table
10. Recommendations for Pharmacological Cardioversion
of Atrial Fibrillation of Less Than or Equal to 7 Days'
Duration.
Table
11. Recommendations for Pharmacological Cardioversion
of Atrial Fibrillation of More Than 7 Days' Duration.
Table
12. Recommended Doses of Drugs Proven Effective
for Pharmacological Cardioversion of Atrial Fibrillation.
Table
13. Recommendations for Use of Pharmacological Agents
to Control the Rate of Ventricular Response to Atrial
Fibrillation.
Table
14. Recommendations for Antithrombotic Therapy in
Patients With Atrial Fibrillation Based on Thromboembolic
Risk Stratification.
Copyright
© 2001 by the American College of Cardiology, American
Heart Association, Inc., and the European Society of
Cardiology
|
